Inhibición de la angiogénesis: - page 7

Current Algorithm
Sq NSCLC Non-Sq NSCLC
EGFR
Mutation
ALK
Rearrangement
Others
First-Line
PLATINUM
DOUBLET +/-
NECITUMUMAB
PEMBROLIZUMAB
(PD-L1+≥50%)
EGFR-TKI ALK-TKI
PLATINUM
DOUBLET
(PEM/BEV)
PEMBROLIZUMAB
(PD-L1+≥50%)
Maintenance NECITUMUMAB/GE
M EGFR-TKI ALK-TKI PEM/BEV
Second-Line
DOCETAXEL +/-
RAMUCIRUMAB
ERLOTINIB
AFATINIB
NIVOLUMAB
PEMBROLIZUMAB
(PD-L1+≥1%)
OSIMERTINIB
(T790M+)
CT
ALECTINIB
CERITINIB
DOCETAXEL
+/- RAMUCIRUMAB
+/- NINTEDANIB
PEMETREXED
ERLOTINIB
NIVOLUMAB
PEMBROLIZUMAB
(PD-L1+≥1%)
Advanced NSCLC Therapies